Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ADHD Drug MedGuides Show FDA’s Focus On Consumer Risk Communications

Executive Summary

FDA's requirement that manufacturers of attention deficit/hyperactivity drugs develop patient medication guides illustrates the growing importance to the agency of communicating risks to the public
Advertisement

Related Content

ADHD MedGuide for parents
ADHD MedGuide for parents
As Medication Guide Requirements Increase, FDA Considers Electronic Delivery
As Medication Guide Requirements Increase, FDA Considers Electronic Delivery
ADHD Class Warnings Could Be Strengthened Pending FDA Research
ADHD Class Warnings Could Be Strengthened Pending FDA Research
ADHD Drug Warnings In New Highlights Section Replaces Need For Black Box
Advertisement
UsernamePublicRestriction

Register

PS048063

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel